Search

Displaying results 5201 - 5210 of 9333 in total
  1. Drug

    SCB-2019

    go.drugbank.com/drugs/DB15805
    Investigational

    As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine. … This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture. The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd..

  2. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    The drug was also evaluated in the treatment of retinal detachment and other diseases of the retina. Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011. … A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol.

  3. Drug

    Methylmethionine chloride

    go.drugbank.com/drugs/DB13250
    Experimental

    Methylmethionine chloride may be useful in helping the healing of gastric ulcers. In Japan, it is used as an over the counter product for gastrointestinal health support.

  4. Drug

    Alethine

    go.drugbank.com/drugs/DB05800
    Investigational

    Alethine is studied in the treatment of cancer. It belongs to a family of chemicals called disulfides. … It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.

  5. Drug

    CERE-120

    go.drugbank.com/drugs/DB05637
    Investigational

    CERE-120 is an investigational drug consisting of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. … It was under investigation in clinical trials for the treatment of Parkinson's Disease.

  6. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication … It inhibits dopamine release and alters the firing of dopaminergic neurons.

  7. Drug

    scAAV9.U7.ACCA

    go.drugbank.com/drugs/DB18582
    Investigational

    scAAV9.U7.ACCA is a non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding … Developed by Nationwide Children’s Hospital, it is being investigated for the treatment of Duchenne muscular dystrophy.

    Synonyms: non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA
  8. Drug

    Glypromate

    go.drugbank.com/drugs/DB05633
    Experimental

    In December 2008, the company discontinued further development of the drug after it failed to show an observable effect. … Neuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for the

  9. Drug

    Olendalizumab

    go.drugbank.com/drugs/DB14834
    Investigational

    Olendalizumab is under investigation in clinical trial NCT01883544 (Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects).

  10. Drug

    Obicetrapib

    go.drugbank.com/drugs/DB14890
    Investigational

    Obicetrapib is under investigation in clinical trial NCT02241772 (A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)).